Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events

IMPORTANCE: In the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, the anti-inflammatory monoclonal antibody canakinumab significantly reduced the risk of recurrent cardiovascular events in patients with previous myocardial infarction (MI) and high-sensitivity C-reactive prote...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Cardiol
Autors principals: Sehested, Thomas S. G., Bjerre, Jenny, Ku, Seul, Chang, Andrew, Jahansouz, Alison, Owens, Douglas K., Hlatky, Mark A., Goldhaber-Fiebert, Jeremy D.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439626/
https://ncbi.nlm.nih.gov/pubmed/30649147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2018.4566
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars